Investing.com - Lineage Cell Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Lineage Cell Therapeutics announced earnings per share of $-0.040 on revenue of $3M. Analysts polled by Investing.com anticipated EPS of $-0.030 on revenue of $3.82M.
Lineage Cell Therapeutics shares are down 28.35% from the beginning of the year and are trading at $1.320 , down-from-52-week-high.
Lineage Cell Therapeutics shares lost 0.75% in after-hours trade the report.
Lineage Cell Therapeutics follows other major Healthcare sector earnings this month
Lineage Cell Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar